Stayble Therapeutics AB (STABL) AI Stock Analysis

• Market Cap: kr25.71M
• Dividend Yield: N/A
• Average Volume (3M): 312.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: 63.82%
• Country: SE
• Employees: 2
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 64,359,795
• 10 Day Avg. Volume: 400,834
• 30 Day Avg. Volume: 312,187
• PEG Ratio: -0.05
• Price to Book (P/B): 2.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Stayble Therapeutics AB's overall stock score is heavily influenced by its weak financial performance, characterized by consistent net losses and negative cash flow. Technical analysis indicates a bearish trend, while valuation metrics reflect the financial struggles typical of early-stage biotechnology firms. The stock lacks positive catalysts such as earnings calls or corporate events, further weighing down its overall score.

Stayble Therapeutics AB Business Overview & Revenue Model

Company Description

Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.

How the Company Makes Money

Stayble Therapeutics AB generates revenue through the development and eventual commercialization of its proprietary treatment solutions for degenerative disc disease. The company primarily invests in clinical trials and research to bring its products to market, aiming to license its technologies to larger pharmaceutical companies upon successful trial results. Significant revenue streams are expected to arise from licensing agreements, milestone payments, and royalties from sales of approved therapies. Partnerships with research institutions and healthcare organizations may also contribute to its earnings by bolstering research capabilities and expanding market reach.

Stayble Therapeutics AB Financial Statement Overview

Summary

Stayble Therapeutics AB faces considerable financial challenges, primarily due to its inability to generate revenue while incurring high operating costs, leading to consistent net losses. The balance sheet shows financial solidity with no debt, but profitability metrics are weak. Overall, the company needs to improve its revenue generation and cost management to achieve financial sustainability.

Income Statement

Stayble Therapeutics AB has struggled to generate revenue, with a TTM revenue of $10,000, a significant increase from $0 in previous years. However, the company posts a substantial net loss of $12.4 million and negative EBIT and EBITDA margins, indicative of high operating expenses and limited revenue generation capacity within the biotechnology industry.

Balance Sheet

The balance sheet shows a strong equity base with a debt-to-equity ratio of 0, as the company has no debt. However, the equity ratio is 74.27%, reflecting financial stability. The company's ROE is negative, driven by significant net losses, which is concerning in terms of generating shareholder value.

Cash Flow

The company's cash flow statement indicates significant negative operating cash flow of $14.7 million TTM. Free cash flow is also negative, reflecting cash outflows that are not being offset by operating income. The operating cash flow to net income ratio is unfavorably negative, highlighting cash consumption without corresponding revenue generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-13.03M	0.00	0.00	0.00	0.00
EBITDA	-12.37M	309.41K	0.00	0.00	0.00
Net Income	-12.42M	-23.74M	-24.23M	-12.04M	-16.05M
Balance Sheet
Total Assets	9.26M	21.70M	19.15M	43.64M	18.00M
Cash, Cash Equivalents and Short-Term Investments	2.19M	14.08M	12.85M	37.47M	10.87M
Total Debt	0.00	850.00K	850.00K	850.00K	850.00K
Total Liabilities	2.38M	5.19M	3.87M	3.83M	2.45M
Stockholders Equity	6.87M	16.51M	15.28M	39.81M	15.55M
Cash Flow
Free Cash Flow	-14.67M	-23.54M	-24.89M	-9.63M	-23.98M
Operating Cash Flow	-14.67M	-23.54M	-24.89M	-9.63M	-23.98M
Investing Cash Flow	0.00	0.00	1.00K	-1.00K	0.00
Financing Cash Flow	2.78M	24.96M	0.00	36.15M	31.19M

Stayble Therapeutics AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STABL, the sentiment is Negative. The current price of 0.42 is above the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.43, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.80 is Neutral, neither overbought nor oversold. The STOCH value of 20.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:STABL.

Stayble Therapeutics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	kr46.73M	―		8.47%	-94.12%	-25.83%
Sector *	52 Neutral	kr5.63B	10.38	-63.86%	1.96%	27.11%	26.73%
LIDDS	37 Underperform	kr12.28M	―	-107.11%	―	―	94.98%
STABL	34 Underperform	kr25.71M	―	-105.54%	―	―	63.82%
QUIA	32 Underperform	kr7.43M	―	-209.54%	―	―	97.86%